These data illustrate that the relationship between TR activation and insulin sensitivity is complex and suggests that although TR agonists may have value in treating NAFLD, their effect on insulin sensitivity must also be considered. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.